Screener
Viking Therapeutics VKTX Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Viking Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: Viking Therapeutics’s 10-Q, filed April 30, 2026.
- Filed
- Apr 29, 2026, 9:50 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-193315
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Cash flows from financing activities | ||
| Proceeds from exercises of stock options and other stock issuances | 450 | 349 |
| ATM offering, net of fees | 11,627 | — |
| Net cash provided by financing activities | 12,077 | 349 |
| Net increase (decrease) in cash and cash equivalents | (47,710) | 11,263 |
| Cash and cash equivalents beginning of period | 165,810 | 26,676 |
| Effect of exchange rate changes on cash | 16 | 1 |
| Cash and cash equivalents end of period | $118,116 | $37,940 |
Item 1. Financial Statements
FAQ
- What is Viking Therapeutics's financing cash flow?
- Viking Therapeutics (VKTX) reported financing cash flow of $12.08M in Q1 2026.
- How has Viking Therapeutics's financing cash flow changed year-over-year?
- Viking Therapeutics's financing cash flow increased by 3360.5% year-over-year, from $349K to $12.08M.
- What is the long-term trend for Viking Therapeutics's financing cash flow?
- Over 4 years (2021 to 2025), Viking Therapeutics's financing cash flow has grown at a 80.9% compound annual growth rate (CAGR), from $7.14M to $76.44M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about Viking Therapeutics's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude